AMPH — Amphastar Pharmaceuticals, Inc.

Is AMPH overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Drug Manufacturers - Specialty & Generic

Overbought As of August 19, 2026

Amphastar Pharmaceuticals, Inc. (AMPH) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Drug Manufacturers - Specialty & Generic) last closed at $21.74. The rating moved from Neutral to Overbought on August 13, 2026.

See all overbought Healthcare stocks →

AI analysis

Amphastar Pharmaceuticals, Inc. (AMPH) is a specialty generics and injectable-focused manufacturer with operational strengths in sterile production that support stable near-term cash flows. Current market conditions have been calm with limited macro or geopolitical drivers, leaving firm-specific fundamentals and regulatory posture as primary drivers. Positive thematic demand for biologics/CDMO services provides tailwinds to players with manufacturing capabilities, but Amphastar’s exposure is partial and dependent on product mix. Lack of recent public filing detail constrains visibility on balance-sheet trends and upcoming catalysts. Key upside scenarios include steady sales from core injectable franchises and successful contract or product wins; downside scenarios are driven by regulatory compliance events, accelerated pricing pressure, or concentrated product disruption. Overall, the outlook suggests near-term rangebound trading with sensitivity to regulatory and reimbursement developments.

Key factors

  • Established specialty generic injectables and inhalation product portfolio providing steady revenue streams and defensive demand characteristics
  • Manufacturing capability for sterile injectables gives commercial and contract-manufacturing optionality versus peers
  • Limited near-term macro/policy shocks in the market window reduced headline volatility, supporting short-term stability
  • Sector-level bullish demand for biologics/CRO/CDMO services is a constructive thematic, though Amphastar’s exposure is partial and product-specific
  • No recent EDGAR/filing comparison available, which limits visibility into upcoming catalysts or balance-sheet nuance

Risks

  • FDA inspections, warning letters or manufacturing compliance issues that can disrupt sterile injectable production and revenue
  • Persistent generic-pricing pressure and payer reimbursement rationalization that can compress margins
  • Product concentration and client/customer concentration risk if a few products drive a large share of sales
  • Supply-chain disruptions for key raw materials or device components affecting output and shipment timing
  • Litigation or liability risks tied to specialty injectables or device products (recalls, product claims)

See today's live rating, score and targets

Members see the live hourly rating for AMPH — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.